Skip to content

Bioventus BVS Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

Medtronic logo
MedtronicMDT
Globus Medical logo
Globus MedicalGMED
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
Avanos Medical logo
Avanos MedicalAVNS
Axogen logo
AxogenAXGN
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's accounts receivable, credit loss expense (reversal)?
Bioventus (BVS) reported accounts receivable, credit loss expense (reversal) of $230K in Q1 2026.
How has Bioventus's accounts receivable, credit loss expense (reversal) changed year-over-year?
Bioventus's accounts receivable, credit loss expense (reversal) decreased by 64.6% year-over-year, from $650K to $230K.
What is the long-term trend for Bioventus's accounts receivable, credit loss expense (reversal)?
Over 3 years (2021 to 2025), Bioventus's accounts receivable, credit loss expense (reversal) has grown at a 37.3% compound annual growth rate (CAGR), from $485K to $1.26M.